+39 06 5782665
contact@donawa.com
Italy - UK - USA

COMPANY NEWS

Maria Donawa interviewed by MEDTECH INSIGHT

Donawa Lifescience President, Maria E. Donawa, M.D., has been interviewed by Amanda Maxwell of MEDTECH INSIGHT on the subject of European medical device guidance document MDCG 2024-3 concerning clinical investigation plans in the journal dated 8 April 2024. The guidance, full title ‘Guidance on the content of the clinical investigation plan for clinical investigations of…

Maria Donawa posts article on device clinical evaluation plans on LinkedIn

Donawa Lifescience President, Maria E. Donawa, M.D., has authored a ‘Regulatory Recap’ article on LinkedIn titled ‘CEPs: Parameters vs outcome parameters, what’s the difference?’ The topic arises because of confusion among manufacturers, notified bodies, and competent authorities regarding the interpretation of certain requirements of the EU Medical Device Regulation (MDR, 2017/745) for clinical evaluation plans…

Maria Donawa spoke at the 8th EAAR Annual Conference on 26-27 February 2024

The 8th EAAR Annual Conference on New Medical Device Regulations (RMD2024) took place in Brussels, Belgium, on 26-27 February 2024, featuring speakers from across the MedTech industry, including regulators and notified bodies. Organized by the European Association of Authorised Representatives (EAAR), the conference served as an inclusive platform for all stakeholders across the both medical…

Global News

FDA draft guidance addresses medical misinformation

The US Food and Drug Administration (FDA) has proposed a draft guidance that would give medical device manufacturers more leeway in responding to misinformation about their products. The guidance comes as the agency has spent the past few years trying to dispel COVID-era misinformation that may have caused thousands of deaths. On 8 July 2024,…

New and revised guidance documents available in Europe

The following new guidance documents for device manufacturers placing devices on the European market have been published in recent weeks: MDCG 2024-1-5: Urogynaecological Surgical Mesh Implants used for Pelvic Organ Prolapse repair and Stress Urinary Incontinence MDCG 2022-13 Rev.1: Designation, re-assessment and notification of conformity assessment bodies and notified bodies MDCG 2024-10: Clinical evaluation of…

FDA recommends steps to improve diversity in clinical trials

The US Food and Drug Administration (FDA) has recommended steps for drugmakers and medical device makers to improve racial, ethnic and other diversity in their clinical trials. The draft guidance, “Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies,” includes suggestions for companies and researchers conducting trials on how to…